Publications by authors named "A L Graber"

Background: Dengue is the most prevalent mosquito-borne viral disease and a major public health problem worldwide. Most primary infections with the four dengue virus serotypes (DENV1-4) are inapparent; nonetheless, whether the distribution of symptomatic versus inapparent infections by serotype varies remains unknown. Here, we present (1) the evaluation of a DENV1-4 envelope domain III multiplex microsphere-based assay (EDIII-MMBA) to serotype inapparent primary infections and (2) its application leveraging 17 years of prospective sample collection from the Nicaraguan Pediatric Dengue Cohort Study (PDCS).

View Article and Find Full Text PDF

Unlabelled: The practice of clinical informed consent in America is governed by over 100 years of case law. Although predominant ethics resources for behavior analysts offer some guidance regarding the provision of clinical informed consent, such guidance remains limited. The goal of this article is thus to expand the contemporary literature on clinical informed consent in behavior analysis by providing a historical and contemporary guide to relevant case law.

View Article and Find Full Text PDF

Our goal, taking Tourette syndrome as a case example, is to introduce neurologists to, and motivate discussion on, the neurodiversity paradigm. This philosophical construct considers some neurologic conditions in diversity, instead of simply disease. Moving from philosophical idea to empirical construct draws from patient and family perspectives on (1) quality of life and discrimination, (2) disability pride, and (3) unique profiles of different patient cohorts.

View Article and Find Full Text PDF

Dengue is the most prevalent mosquito-borne viral disease and a major public health problem worldwide. Most primary infections with the four dengue virus serotypes (DENV1-4) are inapparent; nonetheless, whether the distribution of symptomatic versus inapparent infections by serotype varies remains unknown. Here, we present (1) the evaluation of a multiplex DENV1-4 envelope domain III multiplex microsphere-based assay (EDIII-MMBA) to serotype inapparent primary infections and (2) its application leveraging 17 years of prospective sample collection from the Nicaraguan Pediatric Dengue Cohort Study (PDCS).

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effectiveness and safety of repotrectinib, a new ROS1 tyrosine kinase inhibitor, in treating advanced solid tumors, focusing on fusion-positive non-small-cell lung cancer (NSCLC) and resistance mutations like G2032R.
  • The phase 2 trial involved patients who had not previously received ROS1 TKIs, showing a 79% response rate among these individuals, with a median response duration of 34.1 months.
  • Common side effects reported included dizziness (58%), dysgeusia (taste changes, 50%), and paresthesia (tingling sensations).
View Article and Find Full Text PDF